Objective Autoimmune cerebellar ataxias were recently reported to be treatable. However, the proportion of patients with cortical cerebellar atrophy of unknown etiology with autoimmune-associated cerebellar ataxia and the actual effectiveness of immunotherapy in these diseases remain unknown. Methods We measured the level of autoantibodies (including anti-gliadin antibody, anti-glutamic acid decarboxylase (GAD) antibody, and anti-thyroid antibody) in 58 Japanese patients with cerebellar ataxia, excluding those with multiple system atrophy, hereditary spinocerebellar ataxia, cancer, or those who were receiving phenytoin, and the efficacy of immunotherapy was assessed. Results Thirty-one of 58 (53%) patients were positive for anti-GAD antibody, anti-gliadin antibody, or antithyroid antibody. Seven of the 12 anti-gliadin antibody-positive patients, three of the four anti-GAD antibody-positive patients, and three of the six anti-thyroid antibody-positive patients responded well to immunotherapy, indicating that 59% of patients with ataxia-associated antibody-positive cerebellar ataxia undergoing immunotherapy responded well. Conclusion Some patients with cerebellar ataxia have autoimmune conditions and diagnosing autoimmune cerebellar ataxia is therefore an important component in the care of patients with this disease entity.
Introduction
Autoimmune cerebellar ataxias, including anti-glutamic acid decarboxylase (GAD) antibody-positive cerebellar ataxia (1, 2) , gluten ataxia (3, 4) , and Hashimoto's encephalopathy (5, 6) , were recently reported to be treatable.
However, the proportion of patients with cortical cerebellar atrophy of unknown etiology with autoimmuneassociated cerebellar ataxia and the actual effectiveness of immunotherapy in these diseases remain unknown.
We conducted this study to determine the proportion of patients with cerebellar ataxia who were positive for anti-GAD antibody, anti-gliadin antibody, and/or anti-thyroid antibody. We furthermore aimed to determine the efficacy of immunotherapy in those patients and to characterize the role of autoimmunity in cerebellar ataxia. provided informed consent to participate in the study.
We enrolled idiopathic cerebellar ataxia patients in this study. The entry criteria were as follows: 1) patients with cerebellar ataxia and the primary complaint of dizziness/unsteady gait who were seen at Tokyo Medical University Hachioji Medical Center in 2005 or later; 2) lower limb muscle strength of MMT4+ or greater; 3) ataxia not due to deep sensory impairment; 4) inability to stand on one leg for 10 seconds or produce a tandem gait for 10 steps or more; 5) ataxia findings in a heel-knee test; and 6) magnetic resonance imaging (MRI) findings of cerebellar atrophy or MRI findings of no abnormalities outside the cerebellum that cause dizziness/unsteady gait. Additionally, patients with multiple system atrophy or hereditary spinocerebellar degeneration and patients receiving phenytoin were excluded. A whole-body computed tomographic scan, fecal occult blood test, and tumor marker test were performed, and patients with cancer were excluded. This study also included cases that had been previously reported (1, 2) .
We measured the level of autoantibodies, including antigliadin IgA and IgG antibodies, anti-deamidated gliadin peptide (DGP) IgA and IgG antibodies, anti-GAD antibody, anti-thyroid antibody, anti-nuclear antibody, anti-DNA antibody, rheumatoid factor, P-anti-neutrophil cytoplasmic antibody (ANCA), C-ANCA, and anti-SS-A antibody in the enrolled patients. Moreover, for patients suspected of having anti-GAD antibody-associated ataxia, the cerebrospinal fluid was tested for anti-GAD antibody. Anti-gliadin antibodies and anti-DGP antibodies were measured with an enzymelinked immunosorbent assay. Anti-GAD antibody and antithyroid antibodies were measured with a radioimmunoassay.
Anti-gliadin antibodies have been recognized to be important factors in the pathogenesis of autoimmune cerebellar ataxia. Therefore, patients with anti-gliadin antibody or anti-DGP antibody were classified into the anti-gliadin antibodypositive group. The anti-thyroid antibody-positive patients without anti-gliadin antibody, anti-DGP antibody or anti-GAD antibody were classified into the anti-thyroid antibody-positive group.
All patients with anti-gliadin antibody or anti-DGP antibody were instructed to follow a gluten-free diet. When the patients' symptoms impaired the activities of daily living and the patients requested immunotherapy, they were treated with immunotherapies including steroid therapy, intravenous immunoglobulin (IVIG) therapy, and immunoadsorption plasmapheresis, and the efficacy of these treatments was assessed.
We determined the therapy to be effective when the following three criteria were met: 1) International Cooperative Ataxia Scale for posture and gait disturbances improved by two points or limb ataxia apparently improved; 2) the effectiveness continued for over 1 month and retreatment was effective; and 3) the patients and their family members judged the therapy to be effective.
We diagnosed only the immunotherapy-effective patients with autoimmune cerebellar ataxia, including gluten ataxia, anti-GAD antibody-associated ataxia, and the ataxic form of Hashimoto's encephalopathy.
Results
We enrolled 58 idiopathic cerebellar ataxia patients. Of the 58 patients enrolled, 14 were anti-gliadin or anti-DGP antibody-positive; eight of the patients were anti-GAD antibody-positive; and eighteen patients were anti-thyroid antibody-positive ( Figure) .
Anti-gliadin antibody
Fourteen of the patients were anti-gliadin or anti-DGP antibody-positive, and one (Case 7 in Table 1 ) was also positive for anti-GAD antibody ( Table 1 ). These patients included five men and nine women with a mean age at onset of 56.4 years (range, 7-77 years). Five patients (Cases 2, 4, 5, 7, and 11 in Table 1 ) presented with higher cerebral dysfunction in addition to cerebellar ataxia. MRI revealed marked cerebellar atrophy in five of these 14 patients and mild cerebellar atrophy in seven patients. However, cerebellar atrophy was not clear in two patients. One man (Case 7 in Table 1 ) had diarrhea, however, none of the other patients exhibited digestive symptoms. One woman (Case 5 in Table 1) with epilepsy and myoclonus whose onset was at an early age was diagnosed with celiac disease following a biopsy of the duodenum. Polyneuropathy was seen in two patients (Cases 10 and 13 in Table 1 ).
Seven of these 14 patients received IVIG therapy, and marked improvement occurred in one patient (Case 4 in Table 1), moderate improvement occurred in three patients (Cases 3, 6, and 9 in Table 1 ), and therapy was ineffective in three patients. Steroid therapy was administered to eight patients, of whom four improved (Cases 9, 10, 11, and 13 in Table 1 ). Immunoadsorption therapy was effective in one (Case 9 in Table 1 ) of three patients. In total, immunotherapy was effective in seven (58%) of 12 patients. These Table 1 ) were diagnosed with gluten ataxia.
Of the seven patients in whom the therapy was effective, three patients were positive for anti-SS-A antibody (Cases 3, 4, and 11 in Table 1 ), four patients (Cases 3, 6, 9, and 10 in Table 1 ) were positive for anti-thyroid peroxidase (TPO) antibody, and five patients (Cases 3, 6, 9, 10, and 13 in Table 1) were positive for two or more autoantibodies besides anti-gliadin antibody. Four of the five patients who did not respond to therapy were positive for one or no autoantibodies besides anti-gliadin antibody, and two of these patients were negative for autoantibodies besides anti-gliadin antibody.
Anti-GAD antibody
Seven of the patients (12%) were anti-GAD antibodypositive, but negative for anti-gliadin antibody ( Table 2) . Six (Cases 1, 2, 3, 5, 6, and 7 in Table 2 ) of the seven patients had a low anti-GAD antibody titer, the majority of whom were men (four patients). The cerebrospinal fluid anti-GAD antibody index was elevated in all four patients (Cases 2, 3, 5, and 6 in Table 2 ) in whom it was measured. Four of the seven patients had diabetes, three (Cases 4, 5, and 7 in Table 2) of whom had type I diabetes.
Three (Cases 3, 4, and 6 in Table 2 ) of the four patients receiving IVIG responded well. The response of yearly IVIG gradually declined in a marked responder (Case 6 in Table 2 ) who became non-ambulatory. However, the effectiveness of IVIG and oral steroid therapy has been maintained for 10 years. Her younger brother (Case 3 in Table 2 ) also has cerebellar ataxia. His serum was negative for anti-GAD antibody, however, his anti-GAD antibody titer in the cerebrospinal fluid was relatively high. IVIG and oral steroid therapy improved his ataxia. The other responder (Case 4 in Table 2 ) remained in remission for an extended period and showed gradually declining anti-GAD antibody levels with just one treatment. These three therapy-effective patients were diagnosed with anti-GAD antibody-associated cerebellar ataxia.
Anti-thyroid antibodies
Eighteen of the patients (31%) were anti-thyroid antibody-positive ( Figure) . Ten patients (17%) were antithyroid antibody-positive, but negative for anti-GAD and anti-gliadin antibodies ( Table 3 ). Of the patients with cerebellar ataxia in this study who were positive for anti-thyroid antibody alone, half complained of a headache, with three patients (Cases 2, 4, and 7 in Table 3 ) experiencing migraine headaches. Six of these patients underwent immunotherapy and three (50.0%) responded well. These three therapy-effective patients (Cases 1, 3, and 9 in Table 3 ) were diagnosed with the ataxic form of Hashimoto's encephalopathy.
Of the 22 patients with autoantibody-positive cerebellar ataxia undergoing immunotherapy, 13 (59%) responded well. These 13 therapy-effective patients were diagnosed with autoimmune cerebellar ataxia.
Discussion
In the present study, approximately half of the patients with cerebellar ataxia of unknown etiology in our study were positive for autoantibodies that have been associated with cerebellar ataxia, and more than half of the autoantibody-positive patients undergoing immunotherapy responded well.
Hadjivassiliou et al. investigated the etiologies of sporadic ataxias and found that 37% of the patients studied had gluten ataxia and 2.6% had anti-GAD antibody-positive ataxia. They also found that 47% of patients with idiopathic sporadic ataxias had an autoimmune disease and that 60% were anti-cerebellar antibody-positive (7) . In addition to the study by Hadjivassiliou et al., our study suggests that autoimmunity is an important contributor to sporadic cerebellar ataxias and that diagnosing autoimmune cerebellar ataxia is an important component in the care of patients with this disease entity.
The prevalence of celiac disease in Europe and the US is high, and many reports have been published on gluten ataxia. Conversely, in Asia, celiac disease is extremely rare, and reports are comparatively few (8) . However, in this study, 14 (24%) of 58 patients examined tested positive for anti-gliadin or anti-DGP antibodies. This result confirmed that gluten ataxia is not necessarily rare in Japan. Gluten ataxia should be recognized as an important disease causing cerebellar ataxia in Asia, despite the lower incidence than is observed in Western countries.
Hadjivassiliou et al. reported that the rate of idiopathic cerebellar ataxia associated with anti-GAD antibody was 2.6% (7) , however, at our institution the rate was high at 12%. Additionally, the fact that six of seven patients with anti-GAD antibody-positive cerebellar ataxia in this study had a low antibody titer and that over half of the patients were men also differs from previous reports of anti-GAD antibody-associated cerebellar ataxia. However, slow progressive type I diabetes is reported to have a tendency for lower anti-GAD antibody titers, and men are predominantly affected (9) ; our results are consistent with this.
In 2003, we reported on six patients with low-titer anti-GAD antibody-associated cerebellar ataxia (2) . In this study, we also found that six of seven anti-GAD antibody-positive ataxia patients had low antibody titers, and the cerebrospinal fluid anti-GAD antibody index was markedly elevated in all four patients in whom this could be measured. Moreover, a serum anti-GAD antibody-negative, cerebrospinal fluidpositive patient has been recently reported (10) . To avoid overlooking patients with low-titer anti-GAD antibody positivity when caring for patients with cerebellar ataxia, they must be cared for in a careful manner that includes measuring anti-GAD antibodies in the cerebrospinal fluid.
Shaw et al. defined Hashimoto encephalopathy as meeting the following three criteria: 1) presence of neuropsychiatric symptoms; 2) presence of anti-thyroid antibody; and 3) good reactivity to steroids (11) . Of the patients in this study, three of six who received immunotherapy, including patients in whom IVIG was effective, met the criteria of Shaw et al. The disease concept of the ataxic form of Hashimoto's encephalopathy has not yet been established, however, it is possible that half of the patients who were positive for antithyroid antibody alone could have been cases of the ataxic form of Hashimoto's encephalopathy that respond to immunotherapy.
Anti-NH2 terminal of alpha-enolase (NAE) antibody measurements were taken in four of the patients who were positive for anti-thyroid antibody alone. Two of the patients were positive for anti-NAE antibody and two were negative. Immunotherapy was effective in one of the two positive pa-tients and in one of the two negative patients. Anti-NAE antibody demonstrates a high specificity for Hashimoto's encephalopathy and can be a useful serological diagnostic marker for Hashimoto's encephalopathy (12) , however, because the number of patients in this study was small, the utility of anti-NAE antibody could not be verified.
Of the patients with cerebellar ataxia in this study who were positive for anti-thyroid antibody alone, half complained of a headache, with three patients experiencing migraine headaches; this represents a high rate. Not only is an association present between Hashimoto's encephalopathy and a headache, such as a migraine (13) , but there are also reports of cerebellar ataxia due to migraines (14) , which are frequently accompanied by dizziness. More research on the association among cerebellar ataxia, Hashimoto encephalopathy, and migraines must be conducted in the future.
Five of the seven patients with gluten ataxia in whom immunotherapy was effective were positive for two or more autoantibodies besides anti-gliadin antibody, however, four of the five patients who did not respond to therapy were positive for one or no autoantibodies besides anti-gliadin antibody, of which two patients were negative for autoantibodies besides anti-gliadin antibody. Additionally, regarding the efficacy of immunotherapy, four patients were positive for anti-TPO antibody, and two were positive for anti-SS-A antibody. These results suggest that besides ataxia-associated antibodies, such as anti-gliadin antibody and anti-GAD antibody, the co-existence of other multiple autoantibodies, in particular anti-TPO antibody or anti-SS-A antibody, may be considered a predictor of a good response to immunotherapy.
Concerning the efficacy of immunotherapy for gluten ataxia in previous reports, there are many reports in which IVIG was shown to be effective (15) . A search in the Pub-Med database yielded 21 English reports on anti-GAD antibody-associated cerebellar ataxia, and the treatments that were effective were IVIG in 10 patients (16) , steroid therapy in eight patients (17) , azathioprine in four patients (18) , rituximab in three patients (19) , and plasma exchange in one patient (20) . According to the results of this and previous studies, IVIG and steroid therapy are believed to be effective. However, considering the medical costs, we believe that steroid therapy should be conducted first, and if that alone cannot control the disease or cannot be used due to adverse drug reactions, then IVIG, an immunosuppressive agent, or blood purification therapy should be used as appropriate.
The efficacy assessment criteria used in this study were not just whether a single round of treatment was effective; therapy was only determined to be effective if patients experienced an ongoing therapeutic effect from repeated therapy. For patients with gluten ataxia in whom therapy was markedly effective, ataxia symptom progression was inhibited for 5 years or longer. For patients with anti-GAD antibodyassociated cerebellar ataxia in whom therapy was markedly effective, gait disturbance gradually worsened with once-yearly IVIG therapy, however, the efficacy was sustained. Moreover, after concomitant steroid administration, worsening of gait disturbance was prevented. Therefore, immunotherapy is believed to produce sufficient results in autoimmune cerebellar ataxia, even over a long-term period.
Patients with cerebellar ataxia should be tested for various antibodies including anti-GAD, anti-gliadin, and anti-thyroid antibodies. If cerebellar ataxia with an autoimmune mechanism is suspected, then immunotherapy is worth considering before irreversible Purkinje cell injury occurs.
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